The aim of this study is to determine the relationship between serum galectin-3 (Gal-3) levels and the presence and severity of coronary artery disease(CAD). The effects of rosuvastatin on galectin-3 in patients with acute coronary syndrome is also studied.Design and Method:
The study group was composed of 62 patients with acute coronary syndrome(ACS) and 16 patients with a stable angina pactoris(SAP). The control group was composed of 36 healthy individuals. Patients with CAD were randomly given 10 mg rosuvastatin or 20 mg rosuvastatin treatment for one month. The severity of CAD was determined by the Gensini score; and galectin-3 concentrations were measured via ELISA. All analyses were done with SPSS 17.0 for windows.Results:
Galectin-3 in patients with ACS was significantly higher than in patients with SAP (62.02 ± 12.22 vs 48.31 ± 4.89 pg/ml, p < 0.05). Serum galectin-3 levels were higher in the patient with SAP than in the control group (48.31 ± 4.89 vs 31.74 ± 2.74 pg/mL, p < 0.05). In the correlation analysis, galectin-3 had significant correlation with the Gensini score (r = 0.505, P < 0.05) and hs-CRP level (r = 0.417, P < 0.05). After one month treatment with rosuvastatin, galectin-3 in patients with CAD was significantly reduced (P < 0.05);the reduction of Gal-3 with 20 mg rosuvastatin treatment is much greater than with 10mg (P < 0.05).Conclusions:
Galectin-3 was significantly increased in patients with CAD than that in controls. Galectin-3 was positively correlated with the severity of CAD. Rosuvastatin treatment for one month can reduce the level of Gal-3 in patients with CAD, and 20 mg was more effective than 10 mg.